Product Description: Repotrectinib (TPX-0005) is a potent ROS1 (IC50=0.07 nM) and TRK (IC50=0.83/0.05/0.1 nM for TRKA/B/C) inhibitor. Repotrectinib potently inhibits WT ALK (IC50=1.01 nM). Repotrectinib has anti-cancer activity[1][2].
Applications: Cancer-Kinase/protease
Formula: C18H18FN5O2
References: [1]Dayong Zhai, et al. Abstract 2132: The novel, rationally-designed, ALK/SRC inhibitor TPX-0005 overcomes multiple acquired resistance mechanisms to current ALK inhibitors. Cancer Research. July 2016/[2]Karachaliou N, et al. Common Co-activation of AXL and CDCP1 in EGFR-mutation-positive Non-smallcell Lung Cancer Associated With Poor Prognosis. EBioMedicine. 2018 Mar;29:112-127.
CAS Number: 1802220-02-5
Molecular Weight: 355.37
Compound Purity: 99.93
Research Area: Cancer
Solubility: DMSO : 25 mg/mL (ultrasonic)
Target: Anaplastic lymphoma kinase (ALK);ROS Kinase;Trk Receptor
Deutsch
English
